TG4050

Phase 2Small molecule

TTransgene

TG4050 is one of 40 small molecule programs targeting Head and Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck CancerActive, not recruiting

Head and Neck CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Head and Neck Cancer

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Keytruda

Merck & Co.

Phase 3

18 3

Erbitux

IImclone

Phase 3

45 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

62 5

Neurontin

VViatris Specialty LLC

Approved

4 6

Oxycontin

PProtega

Approved

2 7

Opdivo

Bristol-Myers Squibb

Phase 3

10 8

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 9

Tylenol

KKenvue Brands

Approved

1 10

Marcaine

IInnocoll

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1/2Active, not recruiting

Head and Neck Cancer

NCT04183166

Clinical

Trials by Indication[1]

Head and Neck Cancer1 trial

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Active, not recruiting·TTransgene·Phase 1/2·NCT04183166·80 enrolled

Ovarian Carcinoma1 trial

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Completed·TTransgene·Phase 1·NCT03839524·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TG4050. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TG4050 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TG4050. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Transgene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTransgene

TG4050

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Head and Neck Cancer1 trial

Ovarian Carcinoma1 trial

References

Drug Info

Quick Facts

Related News